MD2 Peptides Inhibit Integrin AlphaVbeta3 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to modulate inflammatory responses and control conditions like sepsis and cancer, as existing interventions fail to adequately target the MD2-integrin interaction, which is critical for inflammatory signaling.
Innovation Solution
Development of peptides with specific amino acid substitutions, such as at residues 20 and 39, that reduce binding to integrin αvβ3, and their use in compositions and methods to inhibit MD2 signaling, including fusion proteins and nucleic acids for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MD2 signaling is activated to mount inflammatory responses, then immune defense capability is improved, but harmful inflammation and tissue damage occur
Solution Approach 1:
The patent introduces a soluble MD2 protein as an intermediary that binds to LPS and integrin αvβ3, preventing the formation of the pathogenic LPS-MD2-TLR4 complex on cell surfaces. This soluble mediator absorbs the harmful signaling function, redirecting it away from TLR4-mediated inflammatory pathways while maintaining immune defense capabilities.
Solution Approach 2:
Instead of blocking TLR4 or integrin directly, the invention inverts the approach by using soluble MD2 to sequester LPS in solution, preventing it from reaching the TLR4 receptor. This reverse strategy stops the harmful signaling cascade at its origin by altering the spatial arrangement of the signaling components.
2Object-affected harmful factors
If integrin αvβ3 is blocked to inhibit MD2 signaling, then inflammatory response is reduced, but normal physiological functions are impaired
Solution Approach 1:
The soluble MD2 acts as a selective intermediary that specifically intercepts LPS-integrin interactions in the context of pathogenic signaling, while leaving normal integrin-mediated physiological processes intact. This targeted mediation approach spares normal physiological functions from disruption.
Solution Approach 2:
The invention applies local quality control by specifically targeting the LPS-binding interface of MD2 and its interaction with integrin αvβ3, rather than broadly blocking all integrin functions. This localized intervention affects only the pathological LPS signaling pathway while preserving other integrin-mediated physiological processes.
3Manufacturing precision
If MD2 mutants with decreased integrin binding are developed, then therapeutic specificity is improved, but binding affinity to LPS may be reduced
Solution Approach 1:
The patent employs parameter changes by systematically varying the amino acid sequence of MD2 to create mutants with modified integrin-binding properties. Through rational mutagenesis and screening, specific residues are altered to decrease integrin affinity while preserving LPS-binding capability, thereby optimizing therapeutic specificity without sacrificing essential binding functions.
Data Source
AI summary
The present invention resides in the discovery that the specific interaction between Myeloid Differentiation factor 2 (MD2) and integrin, especially integrin αvβ3, is involved in cellular signaling mediated by MD2-integrin, such as inflammatory response including sepsis. Thus, this invention provides for a novel method for inhibiting integrin signaling by using an inhibitor of MD2-integrin binding, such as a dominant negative mutant of MD2 without integrin-binding capability. A method for identifying inhibitors of MD2-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, host cells, and corresponding compositions for inhibiting MD2-integrin signaling.